98%
921
2 minutes
20
Background: Uremic cardiomyopathy is commonly presented in chronic kidney disease (CKD), and it severely affects the prognosis of patients with CKD. In the past few decades, the investigation of uremic cardiomyopathy has developed rapidly. However, no report has summarized the situation of uremic cardiomyopathy research to date. This study aimed to evaluate the state of uremic cardiomyopathy research in the last 30 years and identify important topics and achievements, as well as emerging trends through bibliometric analysis.
Materials And Methods: Publications related to uremic cardiomyopathy were collected from Science Citation Index Expanded. HistCite, VOSviewer, CiteSpace, and the Bibliometrix Package were used for bibliometric analysis and visualization, including the analysis of the overall distribution of the annual publication, leading countries, and active institutions and authors, core journals, co-cited references, and keywords.
Results: A total of 2,403 studies related to uremic cardiomyopathy were obtained, and progress related to uremic cardiomyopathy was slower in past 3 years. A total of 10,077 authors from 2,697 institutions in 89 countries or regions reported investigations on uremic cardiomyopathy. The United States of America was the most productive and the most cited country. Myles Wolf, Joseph I Shapiro, and Carmine Zoccali published most articles in uremic cardiomyopathy, and journals in nephrology possessed core status in the field. Phosphate metabolism was the hotspot in uremic cardiomyopathy research in recent years, and future progress may concentrate on phosphate metabolism, endogenous natriuretic factors, and novel biomarkers.
Conclusion: The United States of America and European countries played central roles in uremic cardiomyopathy research, while Chinese scholars should be more involved in this field. Global publications on uremic cardiomyopathy have entered platform stage, and the fibroblast growth factor-23-klotho axis remained a hotspot in this field. Endogenous natriuretic factors and novel biomarkers may be potential directions in future investigations.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314665 | PMC |
http://dx.doi.org/10.3389/fcvm.2022.908040 | DOI Listing |
JACC Adv
August 2025
Sorbonne Université, UPMC Univ Paris 06, INSERM 1146, CNRS 7371, Laboratoire d'Imagerie Biomédicale, Paris, France; Department of Cardiovascular Imaging, Sorbonne Université, Pitié-Salpêtrière University Hospital AP-HP, Paris, France. Electronic address:
Background: Patients with end-stage renal disease (ESRD) are at high cardiovascular risk. The safety and prognostic value of stress cardiovascular magnetic resonance (CMR) in ESRD patients remains unclear as data are lacking due to perceived contrast agent-related risk.
Objectives: The authors aimed to assess the safety and prognostic value of stress CMR in asymptomatic ESRD patients on waitlist for kidney transplantation.
J Vasc Access
July 2025
Department of Vascular Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Central venous obstruction (CVO) is a common complication in hemodialysis (HD) patients that can lead to rare but potentially reversible visual impairment (VI). We report the case of a 50-year-old female with end-stage renal disease and uremic cardiomyopathy, who had received HD through a left radiocephalic arteriovenous fistula (AVF) for 6 years. She presented with progressive swelling in her left arm, chest wall, and face over the past year, along with vision loss and diplopia in the last 6 months.
View Article and Find Full Text PDFBackground: Chronic kidney disease (CKD) is an independent cardiovascular risk factor. Patients with CKD develop uremic cardiomyopathy characterized by activation of the sympathetic nervous system, left ventricular hypertrophy, and accumulation of uremic toxins such as indoxyl sulfate (IS). The aim of this study was to assess the effects of renal denervation (RDN) on uremic cardiomyopathy in a rat model of CKD.
View Article and Find Full Text PDFBMC Nephrol
July 2025
Department of Nephrology, Zhongshan Hospital, Fudan University, No.180, Fenglin Road, Xuhui District, Shanghai, 200032, China.
Background: Uremic cardiomyopathy (UCM) remains the leading cause of cardiovascular mortality in patients with end-stage renal disease (ESRD). Experimental animal models serve as essential tools for elucidating the potential mechanism underlying UCM. However, experimental UCM models are often challenged by inter-individual variability and inconsistent success rates.
View Article and Find Full Text PDFCardiol Clin
August 2025
Division of Nephrology and Hypertension, University Hospitals Cleveland Medical Center, Cleveland, OH, USA; School of Medicine, Case Western Reserve University, Cleveland, OH, USA.
Nonatherosclerotic cardiovascular disease (CVD) in chronic kidney disease (CKD) is highly prevalent and involves distinct pathophysiological mechanisms. Arteriosclerosis, characterized by medial arterial layer thickening and fibrosis, leads to increased arterial stiffness and vascular calcification, driven by disordered bone mineral metabolism. Clinical manifestations of nonatherosclerotic CVD include left ventricular hypertrophy, which occurs in up to 70% to 80% of patients with advanced CKD, heart failure (often with preserved ejection fraction), valvular heart disease, and both fatal and nonfatal arrhythmias.
View Article and Find Full Text PDF